Theravance Biopharma 8-K Confirms NASDAQ Listing, No New Material Events
Ticker: TBPH · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, regulatory-filing
TL;DR
**TBPH filed a routine 8-K confirming its NASDAQ listing, no big news.**
AI Summary
Theravance Biopharma, Inc. filed an 8-K on January 12, 2024, under the 'Other Events' category, indicating no specific new material event but rather a routine filing. This filing confirms the company's registration on the NASDAQ Global Market under the trading symbol TBPH. For investors, this filing primarily serves as a confirmation of their existing public listing status and does not introduce new financial or operational information that would immediately impact stock valuation.
Why It Matters
This filing is largely administrative, confirming Theravance Biopharma's continued listing on the NASDAQ Global Market. It doesn't present new financial or operational news that would directly affect an investor's decision.
Risk Assessment
Risk Level: low — This 8-K filing is administrative and does not disclose any new risks or material events that would impact the company's operations or financial standing.
Analyst Insight
A smart investor would recognize this as a routine administrative filing with no immediate impact on the company's fundamentals or stock price. No specific action is warranted based solely on this filing.
Key Players & Entities
- Theravance Biopharma, Inc. (company) — the registrant filing the 8-K
- NASDAQ Global Market (company) — the exchange where Theravance Biopharma's shares are registered
- TBPH (company) — the trading symbol for Theravance Biopharma, Inc.
- January 12, 2024 (date) — the date of the earliest event reported in the 8-K
FAQ
What is the purpose of this specific 8-K filing by Theravance Biopharma, Inc.?
This 8-K filing, dated January 12, 2024, is categorized under 'Other Events' and primarily serves to confirm the company's registration on the NASDAQ Global Market under the trading symbol TBPH. It does not report a new material event beyond this administrative confirmation.
On what stock exchange are Theravance Biopharma, Inc.'s shares registered?
According to the filing, Theravance Biopharma, Inc.'s Ordinary Shares with $0.00001 Par Value are registered on the NASDAQ Global Market.
What is the trading symbol for Theravance Biopharma, Inc.?
The trading symbol for Theravance Biopharma, Inc. on the NASDAQ Global Market is TBPH.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 12, 2024.
Does this 8-K filing indicate any new financial or operational changes for Theravance Biopharma, Inc.?
No, this 8-K filing, categorized under 'Other Events,' does not indicate any new financial or operational changes. It is a routine administrative filing confirming existing registration details.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-01-16 06:16:14
Key Financial Figures
- $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke
Filing Documents
- tm243112d1_8k.htm (8-K) — 24KB
- 0001104659-24-003852.txt ( ) — 193KB
- tbph-20240112.xsd (EX-101.SCH) — 3KB
- tbph-20240112_lab.xml (EX-101.LAB) — 33KB
- tbph-20240112_pre.xml (EX-101.PRE) — 22KB
- tm243112d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On January 12, 2024, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc. and Theravance Biopharma Ireland Limited, subsidiaries of the Registrant Theravance Biopharma, Inc. (together, "Theravance"), and Mylan Ireland Limited and Mylan Specialty L.P. (together, "Mylan"), entered into a Settlement Agreement (the "Settlement Agreement") with Orbicular Pharmaceutical Technologies Private Limited ("Orbicular) relating to Theravance and Mylan's YUPELRI (revefenacin) inhalation solution. A Theravance entity owns and Mylan is the exclusive sub-licensee of United States Patent Nos. 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531; 11,691,948; 8,017,783; 9,249,099; 10,100,013; 11,649,209; and 11,858,898 (the "Patents-in-Suit"). The Settlement Agreement resolves ongoing patent litigation brought by Theravance and Mylan against Orbicular pursuant to the Hatch-Waxman Act based on Orbicular's filing of an abbreviated new drug application ("ANDA") seeking approval to market a generic version of YUPELRI (revefenacin) inhalation solution prior to expiration of the Patents-in-Suit. Under the Settlement Agreement, Theravance and Mylan granted Orbicular a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market Orbicular's generic version of YUPELRI (revefenacin) inhalation solution in the United States on or after the Licensed Launch Date of April 23, 2039, subject to certain exceptions as is customary in these type of agreements. As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission. The patent litigation previously disclosed by the Company remains pending against four other ANDA filers: Cipla Limited; Eugia Pharma Specialities Ltd.; Lupin Inc.; and Mankind Pharma Ltd.; along with certain affiliates. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to